drug · antibody
mosunetuzumab
Marketedupdated 6mo agoby Genentech Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and follicular lymphoma and 4 investigational indications.
indications
investigational
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(3)
Trials studying mosunetuzumab
- phase1A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- phase2Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
- phase2Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
- phase1Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
- phase2A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- phase2Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
News(7)
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.biopharma_dive · 1mo ago
- Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecificsGenentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.biospace · 1mo ago
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drugUltragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.biopharma_dive · 1mo ago
- Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial winRoche’s T cell engager Lunsumio has passed a Phase 3 trial in a slow-growing type of blood cancer, clearing the path for full approval and a broader label. Lunsumio is a bispecific antibody that ta…endpoints · 2mo ago
- Roche bets up to $1B to advance next-gen bispecifics with DualitasThe partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.biospace · 2mo ago
- Roche, Dualitas team up to find bispecific drugs for immune diseasesThrough a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.biopharma_dive · 2mo ago
- Roche signs $1B deal with Dualitas to pair up on big bispecific screening driveRoche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.fiercebiotech · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that